| Revenue growth | +29% YoY consolidated; acquisitions contribute, organic split unstated. |
|---|---|
| Margins | 24% EBITDA; about 150bps higher excluding Saroglitazar launch spend. |
| Demand visibility | IPM expected to grow 10-11%; branded outperformance of 200-400bps. |
| Management confidence | Upbeat and repetitive; hedges Keytruda and Saroglitazar timelines. |
Growth
Revenue +29% YoY, with acquisitions (Rolvedon via SSHO, Associo) contributing. Organic split not quantified; India branded grew 19% YoY.
Outlook
FY27 EBITDA margin guided at 24%+. Net debt ₹5,200 Cr; management comfortable up to 1x net debt/EBITDA. Saroglitazar FY28 revenue not guided.
Risks
Saroglitazar commercial spend near $100M/yr, with launch timing dependent on FDA queries. Two FDA inspections (SEZ2: 1 observation; Moraya: 5) and a Keytruda biosimilar launch tied to patent litigation.
Last quarter's promises, checked
Delivered
- Guided mid-teens India branded growth → delivered 19% YoY (= BEAT)
- Guided strong double-digit FY27 revenue growth → delivered +29% YoY, acquisition-aided (= BEAT)
Partly delivered
- Guided 300-500bps India outperformance → delivered 200-400bps (= PARTIAL)
- Guided 24%+ FY27 EBITDA margin → delivered 24% (= PARTIAL, at floor)
- Guided April 2027 Saro launch → targeted March 2027, FDA queries pending (= PARTIAL)
Earnings Call Transcript filed with NSE, NSE: ZYDUSLIFE. Summary written with AI assistance from the document.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,197.90
- Market cap
- ₹1,20,537 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 28.8×Sector 42.0×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Business Update
Zydus Lifesciences' subsidiary presented Phase 2b trial data for investigational saroglitazar in MASH at AASLD 2026. The drug showed higher steatohepatitis resolution than placebo, but its safety and effectiveness for this use are not yet established.
Zydus Lifesciences Results Update
Zydus Lifesciences reported Q2 FY27 revenue of Rs. 79,096 mn, up 29% y-o-y. H1 net profit was Rs. 18,859 mn, down 31%.
Zydus Lifesciences Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 7,910 Cr (+29% YoY), EBITDA Rs 1,895 Cr at 24.0% margin, reported PAT Rs 926 Cr (-26.6% YoY). Branded India and North America drove growth; FX and D&A weighed on profit.
Zydus Lifesciences Other Announcement
Zydus Lifesciences board approved appointment of Walker Chandiok & Co LLP as statutory auditors for a five-year term. This follows mandatory rotation of outgoing auditor Deloitte Haskins and Sells LLP.
Zydus Lifesciences Q2 FY27 Results: Net Profit ₹925.5 Cr, Down 26.6% YoY
Zydus Lifesciences Ltd reported revenue from operations of ₹7,910 Cr (+29.2% YoY) and net profit of ₹925.5 Cr (-26.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹925.5 Cr · -26.6% YoY
Zydus Lifesciences Acquisition Worth ₹84 Cr
Zydus Lifesciences acquired Sterling Biotech's API business for Rs. 84 Crore via slump sale. The deal covers fermentation-based API products and is completed.
- Value
- ₹84.00 Cr